Results 271 to 280 of about 73,761 (306)
Some of the next articles are maybe not open access.
Chronopharmacokinetics of Ciclosporin and Tacrolimus
Clinical Pharmacokinetics, 2006The correct use of immunosuppressive drugs has a considerable influence on the prognosis of patients with organ transplants. The appropriate utilisation of the drugs involves the administration of an adequate dosage to reach the blood concentrations that will suppress the alloimmune response, while avoiding secondary toxicities.
BARALDO, Massimo, FURLANUT, Mario
openaire +3 more sources
Tacrolimus metabolite cross-reactivity in different tacrolimus assays
Clinical Biochemistry, 1998Tacrolimus (FK506) is an immunosuppressive drug with great clinical promise. There is a controversy regarding the role of tacrolimus metabolites in immunosuppression and toxicity, and immunoassays and immunophilin binding assays have not been adequately tested for metabolite cross-reactivity.
Diane L Davis +6 more
openaire +3 more sources
Seminars in Veterinary Medicine and Surgery: Small Animal, 1997
Cyclosporine and tacrolimus are potent immunosuppressant agents that have been used extensively in humans, primarily for prevention of transplant rejection but also for the treatment of autoimmune disorders. Both agents have similar mechanisms of action and pharmacokinetic profiles. However, the expected toxicity of the agents is dissimilar.
openaire +3 more sources
Cyclosporine and tacrolimus are potent immunosuppressant agents that have been used extensively in humans, primarily for prevention of transplant rejection but also for the treatment of autoimmune disorders. Both agents have similar mechanisms of action and pharmacokinetic profiles. However, the expected toxicity of the agents is dissimilar.
openaire +3 more sources
Annals of Allergy, Asthma & Immunology, 1999
Objective The focus of this review is to summarize the mechanism of action, animal and clinical studies, and adverse effects of tacrolimus (FK 506) in treatment after solid organ transplantation and in treatment of autoimmune diseases. Data Sources A detailed search of the literature was done.
Erik Letko +4 more
openaire +3 more sources
Objective The focus of this review is to summarize the mechanism of action, animal and clinical studies, and adverse effects of tacrolimus (FK 506) in treatment after solid organ transplantation and in treatment of autoimmune diseases. Data Sources A detailed search of the literature was done.
Erik Letko +4 more
openaire +3 more sources
Drug Interactions with Tacrolimus
Drug Safety, 2002Tacrolimus is a drug for which therapeutic drug monitoring is recommended. The existence of a wide variety of potential drug interactions further supports the current strategy of measuring whole blood tacrolimus concentrations in transplanted patients.
openaire +4 more sources
Tacrolimus in cardiac transplantation
Expert Review of Clinical Immunology, 2007The availability of effective immunosuppressive agents has allowed cardiac transplantation to become an accepted treatment for patients with end-stage heart disease. In recent years, tacrolimus has emerged as a useful alternative to cyclosporine, combined with either azathioprine or the newer antiproliferative agents, mycophenolate mofetil or sirolimus.
Jon A. Kobashigawa, Jignesh Patel
openaire +3 more sources
Tacrolimus in liver transplantation
Expert Opinion on Investigational Drugs, 1999Tacrolimus has been in clinical use for ten years. It was launched in a hail of publicity following the successful treatment of cases with apparently irreversible rejection using conventional immunosuppressive therapies. Since that time, the overall experience with the drug has increased considerably. The purpose of this article is to review tacrolimus
Mervyn H. Davies, Piyawat Komolmit
openaire +3 more sources
Tacrolimus in Dermatologic Disorders
The Annals of Pharmacotherapy, 2001OBJECTIVE: To review the data surrounding the use of tacrolimus for skin disorders. DATA SOURCES: Articles were obtained through a MEDLINE search of English-language literature (1990–May 2000); references of the retrieved publications were further reviewed for relevant literature.
openaire +3 more sources
TACROLIMUS AND MYOCARDIAL HYPERTROPHY
Transplantation, 2000Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac ...
Shinji Uemoto +6 more
openaire +3 more sources
Meltdose Tacrolimus Pharmacokinetics
Transplantation Proceedings, 2016Nonadherence to immunosuppressive therapy contributes to the loss of grafts. One of the problem is the fractioning of immunosuppressive dose. In fact, it was demonstrated that a single daily dose (QD) is associated with an increased adherence to therapy compared with twice daily dosing (BID).
openaire +3 more sources